Bruce Montgomery biotech startup Cardeas Pharma raises $34 million

montgomery1

It has been a good week for the Seattle life sciences community. On Monday, Seattle genomics tool maker NanoString Technologies filed for an initial public offering that could raise up to $86 million. Now, comes word that Cardeas Pharma Corporation, a biopharmaceutical company led by Seattle biotech veteran Bruce Montgomery, has raised $34 million in funding…. Read More…

This 16-year-old is spearheading Seattle’s first biotech hackerspace

katriona1

Katriona Guthrie-Honea had a great idea. Last year, as a freshman at Ingraham High School in Seattle, she taught herself enough biology to make a molecular model of a gene-specific biosensor — yes, as a 15-year-old. More than 300 hours of work led the teen-whiz to the grand prize at 2012 NWABR biotech expo. Even after spending… Read More…

Former oil trader, Yankees part-owner invests in Kineta

kineta11

Seattle-based biotech upstart Kineta announced a new investment partnership with RLB Holdings, a Connecticut-based investment firm that partially owns the New York Yankees and is managed by a former Glencore international oil trader. Actual numbers weren’t released, but RLB invested in two of Kineta’s clinical stage drug programs: Kineta One LLC and Kineta Two LLC. Between Kineta… Read More…

Report: Cardeas Pharma raises $5M

montgomery

Cardeas Pharma, a biotechnology company led by Seattle biotech entrepreneur Bruce Montgomery, has reeled in $5 million in venture financing from Novo Ventures, Avalon Ventures, WRF Capital and others, reports Xconomy. The round is expected to close with up to $7.5 million. Montgomery is a well regarded biotech leader, having previously sold Corus Pharma to Gilead Sciences… Read More…

Gates keeps the bar high in push for malaria eradication

gatesmalariasss

Addressing the Malaria Forum in downtown Seattle this morning, Bill Gates sounded at times like he was back in the tech business, trying to get a reluctant team to think long-term and shoot for an ambitious target — using charts and statistical models to make his case. But Gates never encountered a challenge this big… Read More…

Biotech veteran Henney inducted into Hall of Fame

immunex

Biotech pioneer Christopher Henney has been inducted into the industry’s Hall of Fame, with the announcement made at the annual Biotech CEO Meeting in Laguna Beach, California. Henney is credited with co-founding Immunex, Dendreon and Icos, three of the most important biotechnology companies to emerge in the Seattle area in the past 30 years He… Read More…

Man vs. mosquito: How science is taking aim at malaria now

stefankappe

Seattle is the center of the battle against malaria this week, as scientists and global health leaders descend on the region for the second Malaria Forum, organized by the Bill & Melinda Gates Foundation. The meeting comes four years after the first Malaria Forum, where the Gateses issued a challenge to not just control the… Read More…

Dendreon cuts 500 jobs, sheds a quarter of its workforce

dendreon

Slower-than-expected uptake of its Provenge prostate cancer drug forced Seattle biotech company Dendreon to announce 500 job cuts this afternoon, following through on a restructuring plan announced a month ago. The company had employed more than 1,900 people as of the end of June, about 1,200 of them in its manufacturing operations. Dendron also said… Read More…

Tech Moves: Datacastle hires Craig Blessing; Opscode co-founder Jesse Robbins honored; and more

blessing1

Datacastle, a Seattle company that helps organizations securely protect data as employees access corporate resources via the Web and mobile devices, has named Craig Blessing as vice president of sales and business development. Blessing previously worked at Apple Computer, N2H2, Opsware and most recently Doyenz. “The dramatic growth of laptops and edge devices for enterprise… Read More…

Seattle biotech star Dendreon cuts outlook, signals layoffs

dendreon

Dendreon, one of the great hopes of Seattle’s biotech industry, today reduced its financial projections for the year and said it will be cutting jobs amid lower-than-expected sales of its Provenge drug for prostate cancer. The approval of Provenge by the FDA last year was heralded as Seattle’s biggest biotech breakthrough in nearly a decade…. Read More…